Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGPH20 plus avelumab in chemotherapy-resistant pancreatic cancer
2016-004603-31Phase 2Terminated
- Sponsor
- PH Research
- Start
- Oct 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegvorhyaluronidase alfa and avelumab in pancreatic adenocarcinoma (PDAC), sponsored by PH Research. Primary endpoint: Objective response rate by RECIST v1.1. Started Oct 2017; status: terminated.
02
Drugs
pegvorhyaluronidase alfaavelumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2016-004603-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004603-31.